ClinicalTrials.gg
RecruitingNCT06286189Updated Feb 6, 2025

Trazodone on OSA Endotypes

A Phase 1/2 interventional study of Placebo oral tablet and Trazodone Hydrochloride in Obstructive Sleep Apnea, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Brigham and Women's Hospital · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Sleep Apnea, Obstructive by Brigham and Women's Hospital — 12 open to participants now, 12 under way, none of them phase 3. Sleep Apnea, Obstructive · Brigham and Women's Hospital.

Planned enrollment
26th of 42
18 · median 22
Started
2024
the only one that year
Phase 1/2
13 of 42
7 open now
Primary completion
2026-01
later than 4 of 11 live
Registered
36th of 42
by date

Among the 42 studies in Sleep Apnea, Obstructive by Brigham and Women's Hospital, this one is the 26th largest by planned enrollment, is the only one that started in 2024, is one of 13 in phase 1/2, reaches primary completion later than 4 of the 11 other live ones, and was the 36th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

12 of the 42 studies in Sleep Apnea, Obstructive by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Sleep Apnea, Obstructive by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Some OSA patients with low arousal threshold wake up prematurely during an obstructive event and do not have time for spontaneous upper airway (UA) dilator muscle recruitment. As a consequence they are exposed to apnea and hypopnea cycling. In this protocol the investigators will test the effect of trazodone administered before sleep on OSA traits and OSA severity during sleep.

Read the detailed description

Two overnight home sleep studies will be performed: a drug night and a placebo night. The patient will breath spontaneously (without CPAP) for both nights. On the study nights, subjects be instrumented with a full polygraphy for monitoring sleep, and respiratory events. Trazodone 100 mg will be given 30 min before lights out. At least four hours of sleep with high quality signal acquisition will be required for a study to be judged adequate. After the first overnight study is completed, there will be a one-week washout period prior to crossing over to the other treatment.

03

Conditions studied

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate-to-severe OSA (AHI ≥ 15 events/hr)

Exclusion criteria

Exclusion Criteria:

  • All participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements.
  • Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid).
  • Use of SNRIs/SSRIs.
  • Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition.
  • Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea:
  • Other sleep disorders: periodic limb movements (periodic limb movement arousal index > 10/hr), narcolepsy, or parasomnias.
  • to the study drug (angioedema or urticaria)
  • to DAW2020
  • Use of medications that lengthen
  • Hypokaliemia, hypomagnesemia, uncontrolled thyroid disease
  • Severe claustrophobia.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo capsule 30 min before sleep

    Drug: Placebo oral tablet

  • Experimental
    Trazodone

    Trazodone capsule 30 min before sleep

    Drug: Trazodone Hydrochloride

Interventions

  • DrugPlacebo oral tablet

    Placebo capsule taken 30 min before sleep

  • DrugTrazodoneStudies of TrazodoneTrazodone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Trazodone 100 mg 30 min before sleep

06

What researchers measure

Primary outcomes

  1. Effect of trazodone on arousal threshold (%eupnea)

    Arousal threshold will be calculated non invasively from the home sleep test flow signal

    Time frame: 1 night

Secondary outcomes

  1. Effect of trazodone on apnea hypopnea index (events/h)

    Apnea hypopnea index will be calculated from the home sleep test

    Time frame: 1 night

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Jan 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2024
First posted
Feb 29, 2024
StartActual
Jan 1, 2024
Primary completionEst.
Jan 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06286189
Responsible party
Ludovico Messineo (Assistant Professor, Brigham and Women's Hospital) — Principal investigator
First posted
Feb 29, 2024
Start date
Jan 1, 2024
Primary completion
Jan 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Feb 6, 2025

Study contacts

Ludovico Messineo
Contact
lmessineo@bwh.harvard.edu
(617) 732-4013

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion